![](/images/graphics-bg.png)
Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent
Joint Authors
Sipok, Arkadii
Sardi, Armando
Nieroda, Carol
King, Mary Caitlin
Sittig, Michelle
Gushchin, Vadim
Source
International Journal of Surgical Oncology
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-12-13
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Background.
The role of hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is debated.
Melphalan as a perfusion agent has also demonstrated survival benefit in other recurrent and chemoresistant malignancies.
Thus, we hypothesize that melphalan as a HIPEC agent may improve overall survival (OS) and progression-free survival (PFS) in patients with PC from CRC.
Methods.
A retrospective review of a prospective database of 48 patients who underwent optimal CRS (CC-0/1) and HIPEC from 2001-2016 was performed.
Nineteen had CRS/HIPEC with melphalan (group I) and 29 with mitomycin-C (group II).
Survival was estimated using the Kaplan-Meier method.
Cox regression was used for multivariate analysis.
Perioperative variables were compared.
Results.
Mean age at CRS/HIPEC was 53±10 years.
Median peritoneal cancer index (PCI) was 17 vs 13 in groups I and II, respectively (p=0.86).
PCI≥20 occurred in 9 (47%) and 13 (45%) patients in groups I and II, respectively.
Positive lymph nodes were identified in 8/19 (42%) vs 12/29 (41%) in groups I and II, respectively (p=0.73).
Multivariate analysis identified PCI≥20 as a predictive factor of survival (HR: 7.5).
Median OS in groups I and II was 36 and 28 months, respectively (p=0.54).
Median PFS in groups I and II was 10 and 20 months, respectively (p=0.05).
Conclusions.
CRS/HIPEC with MMC had longer median PFS in PC from CRC.
PCI≥20 was the only independent predictive factor for survival.
Until longer follow-up is available, we recommend using MMC in CRS/HIPEC for PC from CRC.
Further prospective randomized studies are necessary.
American Psychological Association (APA)
Sipok, Arkadii& Sardi, Armando& Nieroda, Carol& King, Mary Caitlin& Sittig, Michelle& Gushchin, Vadim. 2018. Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent. International Journal of Surgical Oncology،Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1175684
Modern Language Association (MLA)
Sipok, Arkadii…[et al.]. Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent. International Journal of Surgical Oncology No. 2018 (2018), pp.1-9.
https://search.emarefa.net/detail/BIM-1175684
American Medical Association (AMA)
Sipok, Arkadii& Sardi, Armando& Nieroda, Carol& King, Mary Caitlin& Sittig, Michelle& Gushchin, Vadim. Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent. International Journal of Surgical Oncology. 2018. Vol. 2018, no. 2018, pp.1-9.
https://search.emarefa.net/detail/BIM-1175684
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1175684